Companies who use misleading advertising to promote drugs and other medical products will be “named and shamed”, the regulator has announced. The Medicines and Healthcare products Regulatory Agency (MHRA) plans to clampdown on poor advertising. It will target inflated claims about a product’s effectiveness, and the use of confusing information. As well as pursuing legal action where appropriate, the MHRA will publish advert reviews on its website. Companies which regularly breach the guidelines will have their whole advertising portfolio scrutinised to make sure they meet the required standards. The MHRA said it would also speed up its advertising review process while making sure investigations were still given thorough and rigorous consideration.
